These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 1329670)

  • 1. [Pharmacokinetic study and side effects of chronic daily administration of oral etoposide].
    Taguchi O; Yamakami T; Machishi M; Gabazza EC; Ibata H; Tsutsui K; Suzuki S
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):2005-9. PubMed ID: 1329670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
    Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
    Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
    Miller AA; Rosner GL; Ratain MJ; Hollis DR; Green MR; Schilsky RL
    Clin Cancer Res; 1997 May; 3(5):719-25. PubMed ID: 9815741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic drug monitoring of 21-day oral etoposide in patients with advanced non-small cell lung cancer.
    Miller AA; Tolley EA; Niell HB
    Clin Cancer Res; 1998 Jul; 4(7):1705-10. PubMed ID: 9676845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Administration of oral etoposide for one year as adjuvant chemotherapy for non-small cell lung cancer-side effect].
    Uchida T; Nakakawaji K; Sakamoto J
    Gan To Kagaku Ryoho; 1996 Dec; 23(14):1967-70. PubMed ID: 8978805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
    Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A sequence-dependent paclitaxel/etoposide phase II trial in patients with non-small cell lung cancer.
    Rosell R; Felip E; Massuti B; González-Larriba JL; Benito D; López-Cabrerizo MP; Salamanca O; Camps C; Puerto-Pica J
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-56-S12-60. PubMed ID: 9331123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Early phase II study of oral administration of etoposide for 21 consecutive days in patients with non-small-cell lung cancer].
    Hayasaka S; Kinuwaki E; Nakabayashi T; Saito R; Komatsu H; Nishikawa H; Ohizumi K; Shimizu T; Nakai Y; Niitani H
    Nihon Kyobu Shikkan Gakkai Zasshi; 1995 Dec; 33(12):1367-1371. PubMed ID: 8821989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of unresectable non-small cell lung cancer (NSCLC) with carboplatin and chronic daily administration of oral etoposide].
    Hirabayashi M; Tanaka Y; Yoshida H; Nakagawa M; Kuno K
    Gan To Kagaku Ryoho; 1994 Jan; 21(1):53-8. PubMed ID: 8291916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prolonged oral etoposide therapy in advanced stage lung cancer].
    Bozóky G; Ruby E; Góhér I; Mohos A; Lengyel M
    Orv Hetil; 1997 Jul; 138(28):1791-5. PubMed ID: 9280873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose optimization of gallium chloride, orally administered, in combination with platinum compounds.
    Collery P; Millart H; Kleisbauer JP; Paillotin D; Robinet G; Durand A; Claeyssens S; Legendre JM; Leroy A; Rousseau A
    Anticancer Res; 1994; 14(6A):2299-306. PubMed ID: 7825963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
    Miller AA; Al Omari A; Murry DJ; Case D
    Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot trial of a combination comprising of consecutive oral administration of UFT, and two-divided administration of CDDP in non-small cell lung cancer.
    Gemma A; Kudoh S; Yoshimura A; Ono Y; Takenaka K; Hayashihara K; Hino M; Shibuya M; Niitani H
    Anticancer Res; 1995; 15(6B):2691-5. PubMed ID: 8669849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crossover clinical study comparing the pharmacokinetics of etoposide (75 mg) administered as 25-mg capsules three times a day versus once a day.
    Aydiner A; Koyuncu H; Tas F; Topuz E; Disci R
    Int J Clin Pharmacol Res; 2000; 20(1-2):21-30. PubMed ID: 11146899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A pilot study of combination chemotherapy with cyclophosphamide, adriamycin, chronic daily dosing of oral etoposide for patients with SCLC ineligible for intensive chemotherapy].
    Fujita A; Takabatake H; Tagaki S; Sekine K
    Gan To Kagaku Ryoho; 1995 Feb; 22(3):389-93. PubMed ID: 7880110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
    Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Long-term oral administration of etoposide in the treatment of patients with advanced non-small-cell carcinoma of the lung. The second phase of a clinical study].
    Jeremić B; Djurić Lj; Jevremović S; Stefanović K; Matović M
    Srp Arh Celok Lek; 1996; 124(3-4):65-8. PubMed ID: 9102821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors.
    Sonnichsen DS; Ribeiro RC; Luo X; Mathew P; Relling MV
    Clin Pharmacol Ther; 1995 Jul; 58(1):99-107. PubMed ID: 7628187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is the optimal dose and duration of treatment with etoposide? II. Comparative pharmacokinetic study of three schedules: 1 x 100 mg, 2 x 50 mg, and 4 x 25 mg of oral etoposide daily for 21 days.
    van der Gaast A; Vlastuin M; Kok TC; Splinter TA
    Semin Oncol; 1992 Dec; 19(6 Suppl 14):8-12. PubMed ID: 1488657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A case of small cell carcinoma of the lung responding well to oral etoposide therapy].
    Nakaoka Y; Haraguchi M; Fujii T; Adachi N; Komatsu T; Ota K; Kurihara N
    Gan To Kagaku Ryoho; 1991 Apr; 18(4):637-9. PubMed ID: 1849393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.